Literature DB >> 11967314

Comprehensive screening for human immunodeficiency virus type 1 subtype-specific CD8 cytotoxic T lymphocytes and definition of degenerate epitopes restricted by HLA-A0207 and -C(W)0304 alleles.

Jeffrey R Currier1, Mark deSouza, Penprapa Chanbancherd, Wendy Bernstein, Deborah L Birx, Josephine H Cox.   

Abstract

For this report, the rapid identification and characterization of human immunodeficiency virus type 1 (HIV-1)-derived broadly cross-subtype-reactive CD8 cytotoxic T lymphocyte (CTL) epitopes were performed. Using a gamma interferon (IFN-gamma) Elispot assay-based approach and a panel of recombinant vaccinia viruses expressing gag, env, pol, and nef genes representing the seven most predominant subtypes and one circulating recombinant form of HIV-1, the subtype specificity and cross-subtype reactivity of a CD8 response were directly measured from circulating peripheral blood mononuclear cells (PBMC). Enhanced sensitivity of detection of CD8 responses from cryopreserved PBMC was achieved using autologous vaccinia virus-infected B-lymphoblastoid cell lines as supplemental antigen-presenting cells. Of eleven subjects studied, six exhibited broadly cross-subtype-reactive CD8-mediated IFN-gamma production (at least seven of eight subtypes recognized) to at least one major gene product from HIV-1. Screening of subjects showing broadly cross-subtype-specific responses in the vaccinia virus-based enzyme-linked immunospot (Elispot) assay using a panel of overlapping peptides resulted in the identification of cross-subtype responses down to the 20-mer peptide level in less than 3 days. Three subjects showed broad cross-subtype reactivity in both the IFN-gamma Elispot assay and the standard chromium release cytotoxicity assay. Fine mapping and HLA restriction analysis of the response from three subjects demonstrated that this technique can be used to define epitopes restricted by HLA-A, -B, and -C alleles. In addition, the ability of all three epitopes to be processed from multiple subtypes of their parent proteins and presented in the context of HLA class I molecules following de novo synthesis is shown. While all three minimal epitopes mapped here had previously been defined as HIV-1 epitopes, two are shown to have novel HLA restriction alleles and therefore exhibit degenerate HLA binding capacity. These findings provide biological validation of HLA supertypes in HIV-1 CTL recognition and support earlier studies of cross-subtype CTL responses during HIV-1 infection.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11967314      PMCID: PMC136178          DOI: 10.1128/jvi.76.10.4971-4986.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  82 in total

Review 1.  Cellular immune responses to HIV.

Authors:  A J McMichael; S L Rowland-Jones
Journal:  Nature       Date:  2001-04-19       Impact factor: 49.962

2.  Efficient processing of an antigenic sequence for presentation by MHC class I molecules depends on its neighboring residues in the protein.

Authors:  M Del Val; H J Schlicht; T Ruppert; M J Reddehase; U H Koszinowski
Journal:  Cell       Date:  1991-09-20       Impact factor: 41.582

3.  Four novel cytotoxic T-lymphocyte epitopes in the highly conserved major homology region of HIV-1 Gag, restricted through B*4402, B*1801, A*2601, B*70 (B*1509)

Authors:  G S Ogg; T Dong; P Hansasuta; L Dorrell; J Clarke; R Coker; G Luzzi; C Conlon; A P McMichael; S Rowland-Jones
Journal:  AIDS       Date:  1998-08-20       Impact factor: 4.177

4.  The HLA-A*0207 peptide binding repertoire is limited to a subset of the A*0201 repertoire.

Authors:  J Sidney; M F del Guercio; S Southwood; G Hermanson; A Maewal; E Appella; A Sette
Journal:  Hum Immunol       Date:  1997-11       Impact factor: 2.850

5.  Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome.

Authors:  R A Koup; J T Safrit; Y Cao; C A Andrews; G McLeod; W Borkowsky; C Farthing; D D Ho
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

6.  HIV-specific cytotoxic T-cell activity in an HIV-exposed but uninfected infant.

Authors:  S L Rowland-Jones; D F Nixon; M C Aldhous; F Gotch; K Ariyoshi; N Hallam; J S Kroll; K Froebel; A McMichael
Journal:  Lancet       Date:  1993-04-03       Impact factor: 79.321

7.  Cross-clade envelope glycoprotein 160-specific CD8+ cytotoxic T lymphocyte responses in early HIV type 1 clade B infection.

Authors:  S E Wilson; S L Pedersen; J C Kunich; V L Wilkins; D L Mann; G P Mazzara; J Tartaglia; C L Celum; H W Sheppard
Journal:  AIDS Res Hum Retroviruses       Date:  1998-07-20       Impact factor: 2.205

8.  HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women.

Authors:  S Rowland-Jones; J Sutton; K Ariyoshi; T Dong; F Gotch; S McAdam; D Whitby; S Sabally; A Gallimore; T Corrah
Journal:  Nat Med       Date:  1995-01       Impact factor: 53.440

9.  HIV-specific cytotoxic T lymphocytes in seropositive individuals.

Authors:  B D Walker; S Chakrabarti; B Moss; T J Paradis; T Flynn; A G Durno; R S Blumberg; J C Kaplan; M S Hirsch; R T Schooley
Journal:  Nature       Date:  1987 Jul 23-29       Impact factor: 49.962

10.  Rapid effector function in CD8+ memory T cells.

Authors:  A Lalvani; R Brookes; S Hambleton; W J Britton; A V Hill; A J McMichael
Journal:  J Exp Med       Date:  1997-09-15       Impact factor: 14.307

View more
  14 in total

1.  A dual color ELISPOT method for the simultaneous detection of IL-2 and IFN-gamma HIV-specific immune responses.

Authors:  Salix Boulet; Michel L Ndongala; Yoav Peretz; Marie-Pierre Boisvert; Mohamed-Rachid Boulassel; Cecile Tremblay; Jean-Pierre Routy; Rafick-P Sekaly; Nicole F Bernard
Journal:  J Immunol Methods       Date:  2006-12-29       Impact factor: 2.303

2.  Control of mesothelin-expressing ovarian cancer using adoptive transfer of mesothelin peptide-specific CD8+ T cells.

Authors:  C-F Hung; Y-C Tsai; L He; T-C Wu
Journal:  Gene Ther       Date:  2007-03-22       Impact factor: 5.250

3.  Broad cross-clade T-cell responses to gag in individuals infected with human immunodeficiency virus type 1 non-B clades (A to G): importance of HLA anchor residue conservation.

Authors:  Mark J Geels; Sheri A Dubey; Kiersten Anderson; Elly Baan; Margreet Bakker; Georgios Pollakis; William A Paxton; John W Shiver; Jaap Goudsmit
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

4.  The immunodominant influenza A virus M158-66 cytotoxic T lymphocyte epitope exhibits degenerate class I major histocompatibility complex restriction in humans.

Authors:  Joanna A L Choo; Jingxian Liu; Xinyu Toh; Gijsbert M Grotenbreg; Ee Chee Ren
Journal:  J Virol       Date:  2014-07-02       Impact factor: 5.103

5.  CD4 responses to conserved HIV-1 T helper epitopes show both negative and positive associations with virus load in chronically infected subjects.

Authors:  M J Boaz; A Waters; S Murad; P J Easterbrook; E D'Sousa; C van Wheeley; A Vyakarnam
Journal:  Clin Exp Immunol       Date:  2003-12       Impact factor: 4.330

6.  Profiling humoral immune responses to P. falciparum infection with protein microarrays.

Authors:  Denise L Doolan; Yunxiang Mu; Berkay Unal; Suman Sundaresh; Siddiqua Hirst; Conrad Valdez; Arlo Randall; Douglas Molina; Xiaowu Liang; Daniel A Freilich; J Aggrey Oloo; Peter L Blair; Joao C Aguiar; Pierre Baldi; D Huw Davies; Philip L Felgner
Journal:  Proteomics       Date:  2008-11       Impact factor: 3.984

7.  Hierarchical targeting of subtype C human immunodeficiency virus type 1 proteins by CD8+ T cells: correlation with viral load.

Authors:  Agatha Masemola; Tumelo Mashishi; Greg Khoury; Phineas Mohube; Pauline Mokgotho; Efthyia Vardas; Mark Colvin; Lynn Zijenah; David Katzenstein; Rosemary Musonda; Susan Allen; Newton Kumwenda; Taha Taha; Glenda Gray; James McIntyre; Salim Abdool Karim; Haynes W Sheppard; Clive M Gray
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

8.  Limited breadth of a T-helper cell response to a human immunodeficiency virus envelope protein.

Authors:  X Zhan; K S Slobod; S Surman; S A Brown; T D Lockey; C Coleclough; P C Doherty; J L Hurwitz
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

9.  Magnitude, breadth, and functional profile of T-cell responses during human immunodeficiency virus primary infection with B and BF viral variants.

Authors:  Gabriela Turk; María Magdalena Gherardi; Natalia Laufer; Mónica Saracco; Renata Luzzi; Josephine H Cox; Pedro Cahn; Horacio Salomon
Journal:  J Virol       Date:  2008-01-09       Impact factor: 5.103

10.  A double-blind randomized phase I clinical trial targeting ALVAC-HIV vaccine to human dendritic cells.

Authors:  Michael A Eller; Bonnie M Slike; Josephine H Cox; Emil Lesho; Zhining Wang; Jeffrey R Currier; Janice M Darden; Victoria R Polonis; Maryanne T Vahey; Sheila Peel; Merlin L Robb; Nelson L Michael; Mary A Marovich
Journal:  PLoS One       Date:  2011-09-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.